The Neuroprotective Effect of Losartan through Inhibiting AT1/ASK1/MKK4/JNK3 Pathway Following Cerebral I/R in Rat Hippocampal CA1 Region

CNS Neuroscience and Therapeutics

Volumn 18, Issue 12, 2012, Pages 981-987

  Zhang, Tian Ling ^a   Fu, Jian Liang ^a   Geng, Zhi ^a   Yang, Jia Jun ^a   Sun, Xiao Jiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

ASK1; AT1; Cerebral ischemia; JNK3; Losartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; APOPTOSIS SIGNAL REGULATING KINASE 1; BETA ARRESTIN; CASPASE 3; CYTOCHROME C; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; NEUROPROTECTIVE AGENT; PROTEIN BCL 2; PROTEIN C JUN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; HIPPOCAMPAL CA1 REGION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INHIBITION KINETICS; MALE; MITOCHONDRION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PROTEIN SECRETION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN ISCHEMIA; CA1 REGION, HIPPOCAMPAL; CELL DEATH; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOPRECIPITATION; LOSARTAN; MALE; MAP KINASE KINASE 4; MAP KINASE KINASE KINASE 5; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE 10; NEURONS; NEUROPROTECTIVE AGENTS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84870464850     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12015     Document Type: Article

References (36)

1. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-730.
2. Reiter E, Lefkowitz RJ. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 2006;17:159-165.
3. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu Rev Physiol 2007;69:483-510.
4. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 2000;148:1267-1281.
5. Proceedings of the 55th International Symposium on Crop Protection. Gent, May 6, 2003. Commun Agric Appl Biol Sci 2003;68:455-912.
6. Schmid CL, Bohn LM. Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther 2009;121:285-293.
7. Buss RR, Oppenheim RW. Role of programmed cell death in normal neuronal development and function. Anat Sci Int 2004;79:191-197.
8. De Zio D, Giunta L, Corvaro M, Ferraro E, Cecconi F. Expanding roles of programmed cell death in mammalian neurodevelopment. Semin Cell Dev Biol 2005;16:281-294.
9. Choi DW. Cerebral hypoxia: some new approaches and unanswered questions. J Neurosci 1990;10:2493-2501.
10. Tsukuda K, Mogi M, Iwanami J, et al. Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT receptor blockade. Biochem Biophys Res Commun 2011;409:275-279.
11. Baydas G, Reiter RJ, Akbulut M, Tuzcu M, Tamer S. Melatonin inhibits neural apoptosis induced by homocysteine in hippocampus of rats via inhibition of cytochrome c translocation and caspase-3 activation and by regulating pro- and anti-apoptotic protein levels. Neuroscience 2005;135:879-886.
12. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.
13. Scott MG, Le Rouzic E, Perianin A, et al. Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. J Biol Chem 2002;277:37693-37701.
14. Wang P, Wu Y, Ge X, Ma L, Pei G. Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J Biol Chem 2003;278:11648-11653.
15. Lee MH, El-Shewy HM, Luttrell DK, Luttrell LM. Role of beta-arrestin-mediated desensitization and signaling in the control of angiotensin AT1a receptor-stimulated transcription. J Biol Chem 2008;283:2088-2097.
16. Tanoue T, Nishida E. Molecular recognitions in the MAP kinase cascades. Cell Signal 2003;15:455-462.
17. Pulsinelli WA, Brierley JB. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 1979;10:267-272.
18. Kathmann M, Bauer U, Schlicker E. CB1 receptor density and CB1 receptor-mediated functional effects in rat hippocampus are decreased by an intracerebroventricularly administered antisense oligodeoxynucleotide. Naunyn Schmiedebergs Arch Pharmacol 1999;360:421-427.
19. Gu Z, Jiang Q, Zhang G. c-Jun N-terminal kinase activation in hippocampal CA1 region was involved in ischemic injury. Neuroreport 2001;12:897-900.
20. Miller WE, McDonald PH, Cai SF, Field ME, Davis RJ, Lefkowitz RJ. Identification of a motif in the carboxyl terminus of beta -arrestin2 responsible for activation of JNK3. J Biol Chem 2001;276:27770-27777.
21. Zhang QG, Wang RM, Yin XH, Pan J, Xu TL, Zhang GY. Knock-down of POSH expression is neuroprotective through down-regulating activation of the MLK3-MKK4-JNK pathway following cerebral ischaemia in the rat hippocampal CA1 subfield. J Neurochem 2005;95:784-795.
22. Hu SQ, Zhu J, Pei DS, et al. Overexpression of the PDZ1 domain of PSD-95 diminishes ischemic brain injury via inhibition of the GluR6.PSD-95.MLK3 pathway. J Neurosci Res 2009;87:3626-3638.
23. Chen S, Li G, Zhang W, et al. Ischemia-induced brain damage is enhanced in human renin and angiotensinogen double-transgenic mice. Am J Physiol Regul Integr Comp Physiol 2009;297:R1526-R1531.
24. Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999;30:2391-2398; discussion 98-9.
25. Liu H, Kitazato KT, Uno M, et al. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies. J Hypertens 2008;26:1435-1445.
26. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
27. Schrader J, Luders S, Kulschewski A, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003;34:1699-1703.
28. Liu H, Liu X, Wei X, et al. Losartan, an angiotensin II type 1 receptor blocker, ameliorates cerebral ischemia-reperfusion injury via PI3K/Akt-mediated eNOS phosphorylation. Brain Res Bull 2012;89:65-70.
29. Scarpidis U, Madnani D, Shoemaker C, et al. Arrest of apoptosis in auditory neurons: implications for sensorineural preservation in cochlear implantation. Otol Neurotol 2003;24:409-417.
30. Bazenet CE, Mota MA, Rubin LL. The small GTP-binding protein Cdc42 is required for nerve growth factor withdrawal-induced neuronal death. Proc Natl Acad Sci USA 1998;95:3984-3989.
31. Guo C, Whitmarsh AJ. The beta-arrestin-2 scaffold protein promotes c-Jun N-terminal kinase-3 activation by binding to its nonconserved N terminus. J Biol Chem 2008;283:15903-15911.
32. Kim HW, Cho KJ, Lee SK, Kim GW. Apoptosis signal-regulating kinase 1 (Ask1) targeted small interfering RNA on ischemic neuronal cell death. Brain Res 2011;1412:73-78.
33. Niu YL, Li C, Zhang GY. Blocking Daxx trafficking attenuates neuronal cell death following ischemia/reperfusion in rat hippocampus CA1 region. Arch Biochem Biophys 2011;515:89-98.
34. Maundrell K, Antonsson B, Magnenat E, et al. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 1997;12:180-189.
35. Szczepanek K, Chen Q, Larner AC, Lesnefsky EJ.Cytoprotection by the modulation of mitochondrial electron transport chain: The emerging role of mitochondrial STAT3. Mitochondrion 2011;12:180-189.
36. Zheng Z, Zhao H, Steinberg GK, Yenari MA. Cellular and molecular events underlying ischemia-induced neuronal apoptosis. Drug News Perspect 2003;16:497-503.